Nature:研究发现多发性硬化相关细胞改变

2019-07-22 鲁亦 中国科学报

近日,《自然》在线发表的一项研究报道了与多发性硬化进展相关的细胞类型特异性改变。研究详细描述了可用于疾病表征的多种生物标志物,以及可供研究人员开发新治疗方法的靶点。

近日,《自然》在线发表的一项研究报道了与多发性硬化进展相关的细胞类型特异性改变。研究详细描述了可用于疾病表征的多种生物标志物,以及可供研究人员开发新治疗方法的靶点。

多发性硬化是一种大脑和脊髓的慢性疾病,由免疫系统错误攻击体内健康神经细胞引起,最终会造成脑损伤。但是,导致多发性硬化的细胞类型特异性机制尚未完全明确。

英国剑桥大学的David Rowitch和同事利用从12名生前患多发性硬化的个体脑部提取的单细胞,对这些单细胞的基因表达模式展开了研究,并与无多发性硬化个体大脑的样本进行对比。研究人员发现,有证据显示,神经系统的皮层神经元和非神经元细胞中的各种应激信号通路会出现上调。

作者在多发性硬化个体的组织中发现了大量名为B细胞的免疫细胞,这些细胞会聚集形成含有病变阶段特异性细胞亚群的细胞团。已知B细胞在多发性硬化中有一定作用,而该研究显示,B细胞清除疗法或有助于治疗多发性硬化的神经退行性症状。

原始出处;

Lucas Schirmer, Dmitry Velmeshev, Staffan Holmqvist, et.al. Neuronal vulnerability and multilineage diversity in multiple sclerosis. Nature 17 July 2019

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883777, encodeId=f6b61883e77a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 09 08:02:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753483, encodeId=ea1b1e534832d, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Jun 05 21:02:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890040, encodeId=bb53189004046, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Jan 14 19:02:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370109, encodeId=53063e010985, content=向科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Mon Jul 22 16:27:02 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2020-06-09 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883777, encodeId=f6b61883e77a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 09 08:02:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753483, encodeId=ea1b1e534832d, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Jun 05 21:02:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890040, encodeId=bb53189004046, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Jan 14 19:02:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370109, encodeId=53063e010985, content=向科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Mon Jul 22 16:27:02 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883777, encodeId=f6b61883e77a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 09 08:02:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753483, encodeId=ea1b1e534832d, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Jun 05 21:02:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890040, encodeId=bb53189004046, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Jan 14 19:02:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370109, encodeId=53063e010985, content=向科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Mon Jul 22 16:27:02 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2020-01-14 jml2009
  4. [GetPortalCommentsPageByObjectIdResponse(id=1883777, encodeId=f6b61883e77a5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jun 09 08:02:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753483, encodeId=ea1b1e534832d, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Jun 05 21:02:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890040, encodeId=bb53189004046, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Jan 14 19:02:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370109, encodeId=53063e010985, content=向科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Mon Jul 22 16:27:02 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2019-07-22 坚强007

    向科研人员致敬!

    0

相关资讯

Radiology:颅脑MRI平扫检出多发性硬化新病灶的准确性

本研究旨在验证是否利用对比剂进行颅脑MRI检查能够影响检出新发MS病灶及陈旧病灶增大的敏感性,随即评估进展间期。

2019 实践指南:多发性硬化病变核磁共振检查评估

MRI检查改善了多发性硬化的诊断,但是MRI成像的诊断标准的不恰当解释和应用可导致误诊。本文主要针对多发性硬化病变的MRI检查的正确认知提供实践指导,内容包括对MRI全面特征的详细说明以及其实其他诊断的建议。

Neurology:矿物质摄入量与多发性硬化风险

由此可见,该研究结果表明矿物质摄入不是MS风险的重要决定因素。

JAMA Neurol:早发性多发性硬化患者认知下降速度增加

研究发现,青少年多发性硬化患者成年后的认知下降速率高于成年患者,需进一步了解早发性多发性硬化症对认知结果影响的机制

NEJM:口服BTK抑制剂治疗多发性硬化

研究认为,复发性多发性硬化症患者每日服用一次75毫克Evobrutinib,可显著减少钆增强病变明数目,但不同疗法年化复发率或残疾进展均无显著性差异

J Neurol Neurosur Ps:自然绝经对多发性硬化的影响

由此可见,自然绝经似乎是MS进展阶段的转折点。更年期后复发率也会降低,但这种影响可能主要是由于衰老和慢性疾病患者转为进展期。吸烟可以加速绝经后的残疾进展。